NCT00211029View on ClinicalTrials.gov

A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins

CompletedOBSERVATIONAL
Enrollment

4,670

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Red-Cell Aplasia, Pure
All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00211029 - A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins | Biotech Hunter | Biotech Hunter